SG
BTAI icon

StoneX Group’s BioXcel Therapeutics BTAI Stock Holding History

StoneX Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2K Buy
+20,684
New +$24.2K ﹤0.01% 1274

Other funds holding BTAI

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $1.02B AUM 45.95% 1-Year Est. Return

StoneX Group's BTAI Position: Q2 2026 in Review

StoneX Group opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 20,684 shares worth $29.2K. The stake represents ﹤0.01% of the portfolio and ranks #1274 among its holdings.

32 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • StoneX Group held 20,684 shares of BioXcel Therapeutics worth $29.2K as of Q2 2026.
  • BioXcel Therapeutics was a new StoneX Group position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1274 holding.
  • 32 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.